Professor, Internal Medicine, University of Michigan Medical School
Gastroenterology
Dr. Hari S. Conjeevaram, MD
|
|
Give Review
Hari S. Conjeevaram, MD is an expert in the field of Gastroenterology. He attended Madras Medical College. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Hari Conjeevaram is a published doctor. He published 64 publications, including: 'Fulminant hepatic failure secondary to malignant melanoma: case report and review of the literature.' Hari S. Conjeevaram is registered with Medicare and accepts Medicare payments.
Publications
- Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade.
- CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation.
- Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver Disease.
- Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.
- Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
- Editorial: Exercise for NAFLD: does intensity matter?
- Metabolic Syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.
- Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience.
- One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
- Prognosis of hepatocellular carcinoma: comparison of 7 staging Systems in an American cohort.
- A simple noninvasive index can predict both significant fibrosis and Cirrhosis in patients with chronic hepatitis C.
- Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver Disease in american patients.
- NAFLD may be a common underlying liver Disease in patients with hepatocellular carcinoma in the United States.
- Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat.
- Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
- Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
- Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma.
- Associations between serum lipids and hepatitis C antiviral treatment efficacy.
- Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection.
- Assessing the validity of self-reported medication adherence in hepatitis C treatment.
- Clinical and histopathologic features of fluoroquinolone-induced liver injury.
- Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
- Serum lipids and their associations with viral levels and liver Disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort.
- Long-term follow-up of liver transplant recipients undergoing cyclosporine withdrawal.
- Occult hepatitis B virus infection: a hidden menace?
- Donor liver uridine diphosphate (UDP)-glucuronosyltransferase-1A1 deficiency causing Gilbert's Syndrome in liver transplant recipients.
- Statistical models for predicting response to interferon-alpha and spontaneous seroconversion in children with chronic hepatitis B.
- Successful combined liver-heart transplantation in adults: report of three patients and review of the literature.
- Rapidly progressive liver injury and fatal alcoholic hepatitis occurring after liver transplantation in alcoholic patients.
- Etiology of hepatitis C: a reassessment.
- Fulminant hepatic failure secondary to malignant melanoma: case report and review of the literature.
- Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel Disease.
- Impact of chronic hepatitis B and interferon-alpha therapy on growth of children.
- Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C.
- Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B.
- Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group.
- Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.
- Gender-dependent reduction of spontaneous motor activity and growth in rats subjected to portacaval shunt.
- Reversal of behavioral changes in rats subjected to portacaval shunt with oral neomycin therapy.
- Studies of "endogenous" benzodiazepine in human hepatic encephalopathy.
- Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.
- Management of chronic viral hepatitis in children.
- Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa.
- Therapy for chronic hepatitis B: nucleoside analogues in adult and pediatric patients.
- Successful use of tacrolimus for initial rejection episodes after liver transplantation.
- Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
- Clinical course and management of inflammatory bowel Disease after liver transplantation.
- Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy.
- Prolonged therapy of chronic hepatitis C with ribavirin.
- Animal models of hepatic encephalopathy and hyperammonemia.
- Modern immunosuppression.
- A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype.
- Night blindness secondary to vitamin A deficiency in a patient with bile duct strictures after liver transplantation.
- Safety of continuous human liver support.
- Bioartificial liver support: report of the longest continuous treatment with human hepatocytes.
- Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy.
- Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: System modifications and clinical impact.
- Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
- Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.
- A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.
- Virologic response and resistance to adefovir in patients with chronic hepatitis B.
- Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C.
- A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.
Schools
Dr MGR Medical University Madras Medical College
Metro Health Med CtrCase Wstn Reserve University
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- ERCP (Endoscopic Retrograde Cholangiopancreatography)
- Hemorrhoidectomy or Excision of Anal Tags
- View All
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Case Western Reserve University - MetroHealth -
Mount Sinai Medical Center -
Madras Medical College
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1831271360 | |
| NPPES Provider LastName | CONJEEVARAM | |
| NPPES Provider FirstName | HARI | |
| NPPES Provider ZIPCode | 481095362 | |
| NPPES Provider State | MI | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 891.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 1.8 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1831271360 |
| Last Name Of The Provider | CONJEEVARAM |
| First Name Of The Provider | HARI |
| View All |
Similar Doctors
|
|
Dr. Andrew D. Rhim, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea Todisco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Darren D. Ballard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Haripriya Maddur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William M. Cooney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick K. Askari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aarti Y. Oza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suraj Gupta, MD |
|
|
Dr. Michelle M. Muza-Moons, MD
This Doctor is OpenDoctor Recommended.
|